Orgenesis Inc. (ORGS) | Investment Case

1. Company Snapshot

1.a. Company Description

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide.The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network.It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient.

The company was formerly known as Business Outsourcing Service, Inc.and changed its name to Orgenesis Inc.in August 2011.

Orgenesis Inc.was incorporated in 2008 and is based in Germantown, Maryland.

Show Full description

1.b. Last Insights on ORGS

Orgenesis Inc.'s recent performance was driven by strategic investments and acquisitions. The company secured up to $5 million in equity funding from Williamsburg Venture Holdings, aimed at accelerating the rollout of its decentralized CGT platform. Additionally, Orgenesis acquired certain assets from Neurocords LLC, expanding its regenerative medicine portfolio with spinal cord injury therapies. This strategic move is expected to enhance access to cost-effective, scalable treatments. The company's focus on advancing cell and gene therapies positions it for growth in the healthcare sector.

1.c. Company Highlights

Last Price	0.25
Change Percentage	-66.67%
Open	0.91
Previous Close	0.75
Market Cap ( Millions)	1
Volume	100
Year High	5.89
Year Low	0.02
M A 50	0.47
M A 200	1.41

FCF Yield	-819.60%
Dividend Yield	0.00%
ROE	-1.10%
Debt / Equity	-72.38%
Net Debt / EBIDTA	-109.02%
Price To Book	-0.49
Price Earnings Ratio	54.57
Price To FCF	-0.12
Price To sales	2.18
EV / EBITDA	-1.17

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Orgenesis (NASDAQ:ORGS) Trading 493.3% Higher – Here’s Why

Oct -22

Source: defenseworld.net

Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies

Mar -06

Source: accessnewswire.com

Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings

Jan -28

Source: accessnewswire.com

Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Aug -29

Source: globenewswire.com

Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

Aug -14

Source: globenewswire.com

Orgenesis Provides Business Update for the First Quarter of 2024

May -21

Source: globenewswire.com

Orgenesis Provides Year End Business Update

Apr -15

Source: globenewswire.com

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

Apr -10

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.43%)

6. Segments

Therapies

Expected Growth: 12.43%

Orgenesis Inc.'s therapies exhibit 12.43% growth driven by increasing demand for point-of-care cell and gene therapies, strategic partnerships, and expansion into new markets. Additionally, advancements in proprietary technologies, such as the Mobile Processing Units and Cellspace platform, enhance efficiency and scalability, further fueling growth.

Octomera

Expected Growth: 11.3%

Octomera's 11.3% growth is driven by increasing demand for point-of-care cell therapy, strategic partnerships, and expansion into new markets. Additionally, Orgenesis' investment in digital platform development and growing adoption of personalized medicine contribute to the segment's growth.

Eliminations

Expected Growth: 9.98%

Orgenesis Inc.'s 9.98% growth is driven by increasing demand for point-of-care cell therapy development and manufacturing services, expansion into new markets, strategic partnerships, and investments in digital platform development. Additionally, the company's focus on decentralized medicine and cell therapy solutions resonates with the growing trend of personalized medicine, further fueling growth.

7. Detailed Products

Point of Care

A platform that enables the development and commercialization of autologous cell therapy products

Mobile Processing Units and Labs

Self-contained, modular laboratories that can be easily transported and set up on-site

Cell Therapy Bioprocessing

A range of services and solutions for the development and commercialization of cell therapies

POCare

A digital platform that enables remote monitoring and management of cell therapy patients

Cell Therapy Development

A range of services and solutions for the development of cell therapies

8. Orgenesis Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Orgenesis Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the biotech industry.

Bargaining Power Of Customers

Orgenesis Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products and services are specialized, making it difficult for customers to switch to alternative providers.

Bargaining Power Of Suppliers

Orgenesis Inc. relies on a few key suppliers for raw materials and equipment. While the company has some bargaining power due to its size and reputation, suppliers still have some leverage due to the specialized nature of the products and services provided.

Threat Of New Entrants

The biotech industry has high barriers to entry, including significant capital requirements, regulatory hurdles, and the need for specialized expertise. This limits the threat of new entrants and provides Orgenesis Inc. with a degree of protection.

Intensity Of Rivalry

The biotech industry is highly competitive, with many established players and new entrants vying for market share. Orgenesis Inc. faces intense competition from companies with similar products and services, which can lead to pricing pressure and reduced market share.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	1381.01%
Debt Cost	9.51%
Equity Weight	-1281.01%
Equity Cost	9.92%
WACC	4.25%
Leverage	-107.81%

11. Quality Control: Orgenesis Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Cidara Therapeutics

A-Score: 4.2/10

Value: 6.8

Growth: 3.2

Quality: 5.4

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

Arcturus Therapeutics

A-Score: 4.2/10

Value: 8.4

Growth: 6.3

Quality: 4.2

Yield: 0.0

Momentum: 5.0

Volatility: 1.0

1-Year Total Return ->

ImmuCell

A-Score: 4.2/10

Value: 4.6

Growth: 3.0

Quality: 4.7

Yield: 0.0

Momentum: 10.0

Volatility: 2.7

1-Year Total Return ->

Zevra Therapeutics

A-Score: 3.9/10

Value: 4.6

Growth: 4.0

Quality: 5.8

Yield: 0.0

Momentum: 6.5

Volatility: 2.3

1-Year Total Return ->

Arvinas

A-Score: 3.5/10

Value: 8.4

Growth: 4.4

Quality: 5.4

Yield: 0.0

Momentum: 0.5

Volatility: 2.0

1-Year Total Return ->

Orgenesis

A-Score: 2.9/10

Value: 7.7

Growth: 4.2

Quality: 5.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

11.36%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

4.25%

Orgenesis Inc. - US68619K2042

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ORGS

1.c. Company Highlights

Better Quality

Cheaper

Weak Momentum

Revenues Miss

More Volatile

Revenues Beats

Fairly Valued

Earnings Miss

Average Quality

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.43%)

6. Segments

Therapies

Expected Growth: 12.43%

Octomera

Expected Growth: 11.3%

Eliminations

Expected Growth: 9.98%

7. Detailed Products

Point of Care

Mobile Processing Units and Labs

Cell Therapy Bioprocessing

POCare

Cell Therapy Development

8. Orgenesis Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Orgenesis Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.25$

Current Price

0.25$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA